OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment

Autor(es)

Rodrigues-Junior, Dorival Mendes ^[1] ; Biassi, Thais Priscila ^[1] ; Carlin, Viviane ^[1] ; Buri, Marcus Vinicius ^[2] ; Torrecilhas, Ana Claudia ^[3] ; Bortoluci, Karina Ramalho ^[1] ; Vettore, Andre Luiz ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Biol Sci, Diadema - Brazil

^[2] Univ Fed Sao Paulo, Dept Biochem, Sao Paulo - Brazil

^[3] Univ Fed Sao Paulo, Dept Pharmaceut Sci, Diadema - Brazil

^[4] Univ Fed Sao Paulo, Lab Biol Mol Canc, Rua Pedro Toledo, 669-11 Andar, BR-04039032 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF MOLECULAR NEUROSCIENCE; v. 66, n. 3, p. 383-389, NOV 2018.
• Citações Web of Science: 1

Resumo

Glioblastoma (GBM) is an incurable disease ranked among the deadliest solid cancers worldwide. A better understanding on the molecular aspects of this malignancy could contribute to the development of new treatment strategies and help to improve survival rates. Previously, our group had shown that GBM patients expressing the cancer/testis antigen Opa Interacting Protein 5 (OIP5) present a longer survival period than the OIP5-negative group. The main goal of this study was to evaluate the OIP5 contribution to GBM tumorigenesis and assess the role of OIP5 in GBM cell response to lomustine, an alkylating agent used in the treatment of this malignancy. So, the effect of OIP5 knockdown was evaluated in A172 and T98G GBM cell lines. Our results demonstrated that downregulation of the OIP5 stimulates glioma cell viability and inhibits cell death-induced necrosis prompted by lomustine. In conclusion, our data shows that OIP5 expression in GBM cells seems to be able to enhance lomustine cytotoxic effects, reinforcing that this gene is a potential therapeutic target and putative molecular biomarker for treatment response in GBM. (AU)

• Processo FAPESP: 11/15118-1 - Análise funcional de antígenos câncer/testículos em glioblastoma.
• Beneficiário: Thaís Priscila Biassi
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 10/20218-2 - Identificação de antíginos câncer-testículo expressos em glioblastomas
• Beneficiário: Karina Ramalho Bortoluci
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 12/01597-8 - ESTUDO FUNCIONAL DOS GENES DCC e TGFBR2 EM LINHAGENS CELULARES DE MIELOMA MULTIPLO
• Beneficiário: Dorival Mendes Rodrigues Junior
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 12/14837-7 - Avaliação do perfil de expressão de microRNAs como marcador diagnóstico de metástases cervicais em pacientes com carcinoma epidermóide de cabeça e pescoço
• Beneficiário: André Lopes Carvalho
• Modalidade de apoio: Auxílio à Pesquisa - Regular